You are here

  • Home
  • Archive
  • Volume 19, Issue 2
  • Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCAs) were stopped, versus continuation with FDCAs

Alerts

Article menu
Download PDFPDF
Abstracts
Drug information (i. Anti-infectives, ii. cytostatics, iii. others)
Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCAs) were stopped, versus continuation with FDCAs
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address